Fulgent Genetics Inc (OQ:FLGT)

Business Focus: Medical & Diagnostic Laboratories

Sector:  Healthcare Industry:  Healthcare Facilities & Services
See Regulatory Filings on SEC
Company Contact
Address: 4399 SANTA ANITA AVE
Tel: 1-415-2174964
Website: https://www.fulgentgenetics.com
IR: See website
Key People
Ming Hsieh
Chairman of the Board, Chief Executive Officer
Jian Xie
President, Chief Operating Officer
Paul Kim
Chief Financial Officer
Hanlin Gao
Chief Scientific Officer, Laboratory Director
Business Overview
Fulgent Genetics, Inc. is a technology-based company with a clinical diagnostic business and a therapeutic development business. The Company's clinical diagnostic business offers molecular diagnostic testing services, genetic testing, and anatomic pathology laboratory services designed to provide physicians and patients with clinically actionable diagnostic information. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its business is built on its technology platform, which includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The Company's technology platform offers a test menu. The Company also offers next-generation sequencing (NGS) services.
Financial Overview
For the nine months ended 30 September 2023, Fulgent Genetics Inc revenues decreased 60% to $218.7M. Net loss totaled $39.7M vs. income of $167.2M. Revenues reflect Institutional segment decrease of 67% to $103.8M, Insurance segment decrease of 52% to $112.7M, United States segment decrease of 62% to $204.1M. Net loss reflects Research and development increase of 40% to $18.6M (expense).
Employees: 1,012 as of Feb 15, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $353.80M as of Sep 30, 2023
Annual revenue (TTM): $286.41M as of Sep 30, 2023
EBITDA (TTM): -$51.57M as of Sep 30, 2023
Net annual income (TTM): -$63.51M as of Sep 30, 2023
Free cash flow (TTM): $21.45M as of Sep 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 29,633,057 as of Nov 1, 2023
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.